Please login to the form below

Not currently logged in
Email:
Password:

Vedanta Biosciences appoints two new heads

Lisa Schopf and Erik Spek join the firm
Vedanta Biosciences Erik Spek

Vedanta Biosciences has appointed Lisa Schopf as head of preclinical development and Erik Spek as head of intellectual property.

Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.

Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.

Spek joins from Epizyme, a clinical stage biopharmaceutical company focused on epigenetic targets, where he worked as director of intellectual property.

Bernat Olle, CEO of Vedanta Biosciences, said: “We are delighted to welcome Lisa and Erik to the team. This is an exiting time for Vedanta, and their experience and leadership will be invaluable as we advance our pipeline of drug candidates and scale our discovery platform.”

14th October 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics